Study #2019-0016
A Phase 2 Study of the Hepcidin Mimetic PTG-300 in Patients with Phlebotomy-Requiring Polycythemia Vera
MD Anderson Study Status
Not Accepting
Treatment Agent
PTG-300, Placebo
Description
This is a Phase 2 study with an open-label dose escalation phase followed by a blinded withdrawal phase and an open label extension. The study is designed to monitor the PTG-300 safety profile and to obtain preliminary evidence of efficacy of PTG-300 for the treatment of phlebotomy-requiring polycythemia vera.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Polycythemia Vera
Study phase:
Phase II
Physician name:
Naveen Pemmaraju
Department:
Leukemia
For general questions about clinical trials:
1-866-403-3911
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.